GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ectin Research AB (XSAT:ECTIN B) » Definitions » 3-Year Sharpe Ratio

Ectin Research AB (XSAT:ECTIN B) 3-Year Sharpe Ratio : N/A (As of Jun. 27, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Ectin Research AB 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-06-27), Ectin Research AB's 3-Year Sharpe Ratio is Not available.


Competitive Comparison of Ectin Research AB's 3-Year Sharpe Ratio

For the Biotechnology subindustry, Ectin Research AB's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ectin Research AB's 3-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ectin Research AB's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Ectin Research AB's 3-Year Sharpe Ratio falls into.


;
;

Ectin Research AB 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Ectin Research AB  (XSAT:ECTIN B) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Ectin Research AB 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Ectin Research AB's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ectin Research AB Business Description

Traded in Other Exchanges
N/A
Address
Pepparedsleden 1, Molndal, SWE, 431 83
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.

Ectin Research AB Headlines

No Headlines